- Home
- SKK vs CANF Comparison
SKK vs CANF Comparison
Compare SKK & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKK
- CANF
- Stock Information
- Founded
- SKK 2013
- CANF 1994
- Country
- SKK Singapore
- CANF Israel
- Employees
- SKK N/A
- CANF N/A
- Industry
- SKK
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- SKK
- CANF Health Care
- Exchange
- SKK NYSE
- CANF Nasdaq
- Market Cap
- SKK 12.0M
- CANF 13.5M
- IPO Year
- SKK 2024
- CANF N/A
- Fundamental
- Price
- SKK $0.65
- CANF $1.03
- Analyst Decision
- SKK
- CANF Strong Buy
- Analyst Count
- SKK 0
- CANF 2
- Target Price
- SKK N/A
- CANF $14.00
- AVG Volume (30 Days)
- SKK 60.3K
- CANF 83.3K
- Earning Date
- SKK 02-14-2025
- CANF 08-29-2025
- Dividend Yield
- SKK N/A
- CANF N/A
- EPS Growth
- SKK 99.13
- CANF N/A
- EPS
- SKK 0.03
- CANF N/A
- Revenue
- SKK $11,301,000.00
- CANF $674,000.00
- Revenue This Year
- SKK N/A
- CANF $461.72
- Revenue Next Year
- SKK N/A
- CANF N/A
- P/E Ratio
- SKK $21.86
- CANF N/A
- Revenue Growth
- SKK 15.80
- CANF N/A
- 52 Week Low
- SKK $0.53
- CANF $0.98
- 52 Week High
- SKK $11.45
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- SKK N/A
- CANF 42.43
- Support Level
- SKK N/A
- CANF $1.00
- Resistance Level
- SKK N/A
- CANF $1.05
- Average True Range (ATR)
- SKK 0.00
- CANF 0.02
- MACD
- SKK 0.00
- CANF 0.00
- Stochastic Oscillator
- SKK 0.00
- CANF 40.00
About SKK SKK HOLDINGS LIMITED
SKK Holdings Ltd is a civil engineering service provider that specializes in subsurface utility works in Singapore. It construct and maintain various public works and infrastructure projects that serve the society and the environment. Its projects are the subsurface work related to projects undertaken by the Public Utilities Board (PUB) and Singapore Telecommunications Limited. The nature of these projects is related to repairing of pumping mains, sewer maintenance and pipe cable laying.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).